---
title: Semaphore's 2024 Confidence Results Revealed
description: Discover the latest insights from Semaphore's 2024 Confidence Results and gain valuable knowledge about the future.
image: https://prev.sema4usa.com/hubfs/images/survey-resized-600.jpg
---

[![Semaphore - Private Equity funds-under-management and technology and market due diligence](https://prev.sema4usa.com/hs-fs/file-1633455679-jpg/Sema_4usa/Semaphore_Private_Equity_funds-under-management_technology_and_market_due_diligence_logo1.jpg)](http://www.sema4usa.com/)

[![Semaphore - Private Equity funds-under-management and technology and market due diligence](https://prev.sema4usa.com/hs-fs/file-1665728779-png/images/logo.png)](http://www.sema4usa.com/)

![Boston London New York](https://prev.sema4usa.com/hs-fs/file-15279406-gif/images/banner_boston_london_new-york.gif)

## [Semaphore's 2024 Confidence Results Revealed](https://prev.sema4usa.com/blog/semaphores-2024-confidence-results-revealed)

- [Tweet](https://twitter.com/share)

Discover the latest insights from Semaphore's 2024 Confidence Survey

*"I’ve got to admit it; it‘s getting better, a little better all the time (can't get much worse).”*

With apologies to the Beatles that their music could belie our industry, this lyric came in a comment to our 16th Annual Semaphore Confidence Survey and seemed to summarize the entirety of the record responses received. Our respondents, while recognizing challenges, were decidedly optimistic about themselves, the state of the industry, their ability to deal with inherent problems, and rather certain that incomes would continue to climb.

Four overriding observations deserve note. First, women respondents more than doubled to 25%. Total participation exceeded 1400 responses, double last year and the largest number we have ever experienced. Artificial Intelligence is anticipated to capture the largest investment market share in 2024, far and away the hottest industry sector. Lastly, despite dismal lack of confidence in the Biden administration, over the three weeks the survey remained open, the expectation of whether the President would be reelected grew from 30% in the initial week to 46% at the end - mirroring recent political polls. Someone else with a higher pay grade than me can analyze whether and how all these connect.

The commentary remained enlightening and entertaining. Please conduct your own review and analysis of our audience opinion and whether you abide by them. Click [here](https://prev.sema4usa.com/hubfs/docs/S4%20Confidence%20Survey%202024%20Result%20Highlights%202.pdf) for the survey results and a representative sampling of commentary on matters of the industry, race, carried interest, sexual harassment, breaking up Big Tech, and whether Sam Altman should be running Open AI – 78% say yes with comments ranging from *“He’s a genius”* to *“He’s a fraud”.*

Results intrigued as usual with definitive confidence in yourselves (82%) and a 4X increase in the economy just twelve months ago (40% have confidence today in the US and 12% International), with a single digit 1% confidence in the US Congress. President Biden confidence rating held steady at just 24% with 58% expressing a lack of no confidence in US national tax and spending policies.

For the first time, less than a majority, 47% of you, earned more in 2023 than the prior year, while 58% expect to do so this year. This is a bounce back in confidence as last year we reported the lowest numbers of increased income expectation ever recorded.

Surprisingly, 56% do not support elimination of carried interest rates compared to 70% last year, with 44% apparently agreeing with one commenter that *“Greed is not good”.*

Our respondents don’t wish to have Big Tech broken up (72%), believe that sexual misconduct, harassment, and gender bias remains a problem (68%), both virtually the same numbers as last year. 51%, a slightly smaller majority than last year at 55%, believe inherent racism is a structural industry obstacle.

Respondents were from 25 states with California, Massachusetts and New York making up 59% of the US response. 38 other countries were represented with 37% of international respondents from Canada, UK and Germany (36% last year).

Males represented 74%, 25% Females and, 1% self-reported Gender X of those participating this year. 9% of you were from PE shops (way down from 24% last year); 34% were VCs; 3% Hedge Funds; 13% LPs; 10% operating executives; 9% Investment Bankers; and 22% third party vendors/advisors to the industry (lawyers, accountants, etc.) – the last two categories were double last year’s proportion.

Back to the Beatles – the song noted is “Getting Better” on the Sgt. Pepper’s album. The initial idea for the song's title came from a phrase often spoken by Jimmie Nicol, the group's stand-in drummer for the Australian leg of their 1964 world tour when he replaced Ringo who was ill. Take a listen [https://www.youtube.com/watch?v=EGlo9LzmOME](https://www.youtube.com/watch?v=EGlo9LzmOME) – here’s hoping things do get better all the time.

Check out the complete results and engaging opinion by clicking [here.](https://prev.sema4usa.com/hubfs/docs/S4%20Confidence%20Survey%202024%20Result%20Highlights%202.pdf)

*Mark DiSalvo is Founder and CEO of Sema4 Inc., dba Semaphore, *[*www.sema4usa.com*](http://www.sema4usa.com)*, a leading global professional services provider to troubled Private Equity, Venture Capital and Hedge funds under management. Semaphore currently holds fiduciary obligations as General Partner for fourteen funds, is a New Markets Tax Credit provider, and advises Limited Partners around the world. Semaphore’s corporate offices are in Boston with offices in Barcelona, Dallas, London, Luxembourg, New York, and Washington DC.*

 

 Topics: [Venture Capital](https://prev.sema4usa.com/blog/topic/venture-capital), [equity](https://prev.sema4usa.com/blog/topic/equity), [private equity funds](https://prev.sema4usa.com/blog/topic/private-equity-funds), [Semaphore](https://prev.sema4usa.com/blog/topic/semaphore), [limited partners](https://prev.sema4usa.com/blog/topic/limited-partners), [turnaround](https://prev.sema4usa.com/blog/topic/turnaround), [technology](https://prev.sema4usa.com/blog/topic/technology), [diligence](https://prev.sema4usa.com/blog/topic/diligence), [small businesses](https://prev.sema4usa.com/blog/topic/small-businesses), [growth equity investments](https://prev.sema4usa.com/blog/topic/growth-equity-investments), [market](https://prev.sema4usa.com/blog/topic/market), [analysis](https://prev.sema4usa.com/blog/topic/analysis), [venture funds](https://prev.sema4usa.com/blog/topic/venture-funds), [private equity](https://prev.sema4usa.com/blog/topic/private-equity), [ethics](https://prev.sema4usa.com/blog/topic/ethics), [ethical standards](https://prev.sema4usa.com/blog/topic/ethical-standards), [business](https://prev.sema4usa.com/blog/topic/business), [Survey](https://prev.sema4usa.com/blog/topic/survey)

### Subscribe by Email

### Most Popular Posts

### Browse by Tag

- [American entrepreneurism (1)](https://prev.sema4usa.com/blog/topic/american-entrepreneurism)
- [analysis (2)](https://prev.sema4usa.com/blog/topic/analysis)
- [Announcements (1)](https://prev.sema4usa.com/blog/topic/announcements)
- [Biotech (2)](https://prev.sema4usa.com/blog/topic/biotech)
- [BOSS (1)](https://prev.sema4usa.com/blog/topic/boss)
- [business (5)](https://prev.sema4usa.com/blog/topic/business)
- [business advisory (4)](https://prev.sema4usa.com/blog/topic/business-advisory)
- [Business Operations (2)](https://prev.sema4usa.com/blog/topic/business-operations)
- [Corporate Growth Planning (2)](https://prev.sema4usa.com/blog/topic/corporate-growth-planning)
- [diligence (13)](https://prev.sema4usa.com/blog/topic/diligence)
- [due diligence (12)](https://prev.sema4usa.com/blog/topic/due-diligence)
- [entrepreneurs (3)](https://prev.sema4usa.com/blog/topic/entrepreneurs)
- [equity (10)](https://prev.sema4usa.com/blog/topic/equity)
- [ethical standards (2)](https://prev.sema4usa.com/blog/topic/ethical-standards)
- [ethics (3)](https://prev.sema4usa.com/blog/topic/ethics)
- [finance advice (2)](https://prev.sema4usa.com/blog/topic/finance-advice)
- [funds under management (6)](https://prev.sema4usa.com/blog/topic/funds-under-management)
- [general partners (14)](https://prev.sema4usa.com/blog/topic/general-partners)
- [growth equity investments (3)](https://prev.sema4usa.com/blog/topic/growth-equity-investments)
- [ILPA (1)](https://prev.sema4usa.com/blog/topic/ilpa)
- [ILPA Principles (1)](https://prev.sema4usa.com/blog/topic/ilpa-principles)
- [investment (11)](https://prev.sema4usa.com/blog/topic/investment)
- [Life Sciences (2)](https://prev.sema4usa.com/blog/topic/life-sciences)
- [limited partners (14)](https://prev.sema4usa.com/blog/topic/limited-partners)
- [LP (5)](https://prev.sema4usa.com/blog/topic/lp)
- [market (3)](https://prev.sema4usa.com/blog/topic/market)
- [market diligence (11)](https://prev.sema4usa.com/blog/topic/market-diligence)
- [market diligence; law firms; (2)](https://prev.sema4usa.com/blog/topic/market-diligence-law-firms)
- [new markets tax credits (2)](https://prev.sema4usa.com/blog/topic/new-markets-tax-credits)
- [Olympics (1)](https://prev.sema4usa.com/blog/topic/olympics)
- [operations (3)](https://prev.sema4usa.com/blog/topic/operations)
- [Pipeline Interviews (3)](https://prev.sema4usa.com/blog/topic/pipeline-interviews)
- [portfolio company (2)](https://prev.sema4usa.com/blog/topic/portfolio-company)
- [private equity (6)](https://prev.sema4usa.com/blog/topic/private-equity)
- [private equity funds (16)](https://prev.sema4usa.com/blog/topic/private-equity-funds)
- [SBIR (1)](https://prev.sema4usa.com/blog/topic/sbir)
- [Semaphore (22)](https://prev.sema4usa.com/blog/topic/semaphore)
- [small businesses (2)](https://prev.sema4usa.com/blog/topic/small-businesses)
- [Strategy Services (1)](https://prev.sema4usa.com/blog/topic/strategy-services)
- [Survey (10)](https://prev.sema4usa.com/blog/topic/survey)
- [technology (12)](https://prev.sema4usa.com/blog/topic/technology)
- [Technology Assessment (3)](https://prev.sema4usa.com/blog/topic/technology-assessment)
- [technology diligence (7)](https://prev.sema4usa.com/blog/topic/technology-diligence)
- [troubled funds (12)](https://prev.sema4usa.com/blog/topic/troubled-funds)
- [turnaround (4)](https://prev.sema4usa.com/blog/topic/turnaround)
- [valley of death (1)](https://prev.sema4usa.com/blog/topic/valley-of-death)
- [VC (7)](https://prev.sema4usa.com/blog/topic/vc)
- [Venture Capital (17)](https://prev.sema4usa.com/blog/topic/venture-capital)
- [venture funds (9)](https://prev.sema4usa.com/blog/topic/venture-funds)

### Posts by Month

- [June 2010 (3)](https://prev.sema4usa.com/blog/archive/2010/06)
- [April 2011 (3)](https://prev.sema4usa.com/blog/archive/2011/04)
- [November 2009 (2)](https://prev.sema4usa.com/blog/archive/2009/11)
- [December 2009 (2)](https://prev.sema4usa.com/blog/archive/2009/12)
- [January 2010 (2)](https://prev.sema4usa.com/blog/archive/2010/01)
- [February 2010 (2)](https://prev.sema4usa.com/blog/archive/2010/02)
- [July 2010 (2)](https://prev.sema4usa.com/blog/archive/2010/07)
- [September 2010 (2)](https://prev.sema4usa.com/blog/archive/2010/09)
- [October 2010 (2)](https://prev.sema4usa.com/blog/archive/2010/10)
- [December 2013 (2)](https://prev.sema4usa.com/blog/archive/2013/12)
- [March 2010 (1)](https://prev.sema4usa.com/blog/archive/2010/03)
- [January 2011 (1)](https://prev.sema4usa.com/blog/archive/2011/01)
- [March 2011 (1)](https://prev.sema4usa.com/blog/archive/2011/03)
- [September 2011 (1)](https://prev.sema4usa.com/blog/archive/2011/09)
- [October 2011 (1)](https://prev.sema4usa.com/blog/archive/2011/10)
- [December 2011 (1)](https://prev.sema4usa.com/blog/archive/2011/12)
- [February 2012 (1)](https://prev.sema4usa.com/blog/archive/2012/02)
- [July 2012 (1)](https://prev.sema4usa.com/blog/archive/2012/07)
- [November 2012 (1)](https://prev.sema4usa.com/blog/archive/2012/11)
- [January 2013 (1)](https://prev.sema4usa.com/blog/archive/2013/01)
- [April 2013 (1)](https://prev.sema4usa.com/blog/archive/2013/04)
- [May 2013 (1)](https://prev.sema4usa.com/blog/archive/2013/05)
- [July 2013 (1)](https://prev.sema4usa.com/blog/archive/2013/07)
- [February 2014 (1)](https://prev.sema4usa.com/blog/archive/2014/02)
- [August 2014 (1)](https://prev.sema4usa.com/blog/archive/2014/08)
- [December 2014 (1)](https://prev.sema4usa.com/blog/archive/2014/12)
- [February 2015 (1)](https://prev.sema4usa.com/blog/archive/2015/02)
- [August 2015 (1)](https://prev.sema4usa.com/blog/archive/2015/08)
- [January 2016 (1)](https://prev.sema4usa.com/blog/archive/2016/01)
- [February 2016 (1)](https://prev.sema4usa.com/blog/archive/2016/02)
- [August 2016 (1)](https://prev.sema4usa.com/blog/archive/2016/08)
- [January 2017 (1)](https://prev.sema4usa.com/blog/archive/2017/01)
- [February 2017 (1)](https://prev.sema4usa.com/blog/archive/2017/02)
- [August 2017 (1)](https://prev.sema4usa.com/blog/archive/2017/08)
- [January 2018 (1)](https://prev.sema4usa.com/blog/archive/2018/01)
- [February 2018 (1)](https://prev.sema4usa.com/blog/archive/2018/02)
- [February 2019 (1)](https://prev.sema4usa.com/blog/archive/2019/02)
- [February 2020 (1)](https://prev.sema4usa.com/blog/archive/2020/02)
- [February 2021 (1)](https://prev.sema4usa.com/blog/archive/2021/02)
- [January 2022 (1)](https://prev.sema4usa.com/blog/archive/2022/01)
- [February 2022 (1)](https://prev.sema4usa.com/blog/archive/2022/02)
- [February 2023 (1)](https://prev.sema4usa.com/blog/archive/2023/02)
- [February 2024 (1)](https://prev.sema4usa.com/blog/archive/2024/02)
- [February 2025 (1)](https://prev.sema4usa.com/blog/archive/2025/02)

- [Home ](http://www.sema4usa.com/)|
- [Services ](http://www.sema4usa.com/Technology-Diligence-and-Funds-Under-Management-Services/)|
- [About Us ](http://www.sema4usa.com/About-our-Funds-Under-Management-and-Technology-and-Market-Due-Diligence/)|
- [Semaphore Client List ](http://www.sema4usa.com/semaphore-client-list/)|
- [Blog ](http://www.sema4usa.com/blog/)|
- [Contact Semaphore ](http://www.sema4usa.com/contact-semaphore/)|
- [Semaphore Connections ](http://www.sema4usa.com/semaphore-connections/)

© 2020 Semaphore. All rights reserved.